Clinical effect of azithromycin combined with montelukast sodium in the treatment of Mycoplasmapneumoniae pneumonia in children
阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的临床效果

摘要

目的 探究小儿肺炎支原体肺炎应用阿奇霉素+孟鲁司特钠联合治疗的效果。方法 研究时间2021年4月到2022年8月，研究患儿共60人，选自临床儿科，随机分成对照组（常规阿奇霉素抗菌治疗）、研究组（阿奇霉素+孟鲁司特钠），每组内患儿30人，比对综合疗效。结果 治疗前两组肺炎患儿免疫指标检测值均较高，治疗后研究组患儿CRP、IgG、IgA和IgM等免疫指标水平均低于对照组 P＜0.05；研究组肺炎患儿咳嗽、发热和肺部啰音等症状消退时间以及住院时间均短于对照组，P＜0.05；治疗前，两组肺功能指标之间差异较小（p＞0.05），治疗后两组患儿肺功能指标均好转，研究组FEVI、PEF和FVC等三项肺功能水平均显著高于对照组，P＜0.05。结论 小儿肺炎支原体肺炎在常规抗菌治疗基础上加用孟鲁司特钠可以有效强化药物协同疗效，改善小儿肺功能，提高机体免疫力。

Abstract

Objective To explore the effect of combined treatment of azithromycin and montelukast sodium in children with Mycoplasma pneumoniae pneumonia.
Methods From April 2021 to August 2022, a total of 60 children were selected from the clinical department of pediatrics and randomly divided into the control group (conventional azithromycin antibacterial treatment) and the study group (azithromycin + montelukast sodium), with 30 children in each group, and the comprehensive efficacy was compared.
Results The levels of CRP, IgG, IgA and IgM in the study group were lower than those in the control group (P < 0.05). The remission time of cough, fever, pulmonary rales and other symptoms and hospital stay in the study group were shorter than those in the control group (P < 0.05). Before treatment, there was little difference in pulmonary function indexes between the two groups (p > 0.05). After treatment, the pulmonary function indexes of the two groups were improved. The levels of FEVI, PEF and FVC in the study group were significantly higher than those in the control group (P < 0.05).
Conclusion   Montelukast sodium on the basis of conventional antimicrobial treatment for Mycoplasma pneumoniae pneumonia in children can effectively strengthen the synergistic effect of drugs, improve the pulmonary function of children, and improve the body immunity.